Skip navigation.
Thu Feb 11 15:33:43 2010 [Write for us] | [Login/Register]
Home

Investing

by Rick Aristotle Munarriz - February 2, 2010 - 0 comments
Not every company is slashing its dividend these days. Some of the market's better performers are easing up on their purse strings, sending more money out to their shareholders.
by Dave Mock - February 2, 2010 - 0 comments
Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the companies behind them -- so individuals can make better investing decisions.
by Matthew Argersinger - February 2, 2010 - 0 comments
Smaller is better? Some might call that idea an affront to a deeply ingrained American mantra of bigger, better, stronger. In the auto business, however, the answer to that question is getting increasingly obvious.
by Austin Edwards - February 1, 2010 - 0 comments
If the last two years have taught me anything, it's that I'm not nearly as smart as I think I am -- and neither is anyone else.
by Nick Kapur - February 1, 2010 - 0 comments
Back in my freshman year of high school, I embarked on an unusual journey. I had no way of knowing it at the time, but it was one that would forever change my life.
by Anders Bylund - January 30, 2010 - 0 comments
Apple (Nasdaq: AAPL) built a tablet computer. Kinda, sorta. So did Dell (Nasdaq: DELL) and Hewlett-Packard (NYSE: HPQ), and nobody knows how many tablets we'll see running the Google (Nasdaq: GOOG) Android softwaresoon enough. So there's a totally legit tablet war brewing; will Apple crush its enemies? Nobody knows.
by Rich Smith - January 30, 2010 - 0 comments
The new RFP is here! The new RFP is here!
by Brian Orelli - January 30, 2010 - 0 comments
Lupus hasn't seen a new drug developed specifically for it in the last 50 years, although Human Genome Sciences and GlaxoSmithKline are close to getting one approved. Merck (NYSE: MRK), Vertex Pharmaceuticals , and others are trying to crack into the hepatitis C market since the current offerings available from Roche and Merck only cure about half the patients they're used in.
by Kris Eddy - January 30, 2010 - 0 comments
The Fool gave out some investing tips this week (as always), sparked some outrage, and turned an investor's eye toward a much-hyped device called the iPad.
by David Lee Smith - January 30, 2010 - 0 comments
The steel industry, while continuing to improve somewhat, is still struggling to recover from economic difficulties. U.S. Steel (NYSE: X), the largest of the domestic steelmakers, has turned in a quarter that was hardly worth writing home about.

Recent comments

The Money Times on Facebook

User login